Shigeo Toda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shigeo Toda has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Shuichiro Matoba
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
14 shared publications Hiroya Kuroyanagi
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
12 shared publications- Yutaka Hanaoka
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
10 shared publications Yutaka Hanaoka
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
9 shared publicationsJin Moriyama
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
8 shared publications- Yusuke Maeda
Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
8 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
Prognostic Impact of Circumferential Resection Margin in Minimally Invasive Surgery for Locally Advanced Rectal Cancer: A Multicenter Prospective Study
Aim: Circumferential resection margin (CRM) status is a well‐established prognostic factor in rectal cancer surgery; however, its long‐term oncological relevance has not been prospectively validated in Japan, where upfront surgery has long been widely used. This study assessed the prognostic impact of CRM in patients with locally advanced rectal cancer treated with minimally invasive surgery. Methods: The PRODUCT trial was a multicenter, prospective, observational study conducted at 18 institutions in Japan. Patients aged ≥ 20 years with clinical stage II or III rectal adenocarcinoma located within 12 cm from the anal verge and scheduled for laparoscopic or robotic surgery were enrolled. CRM positivity was defined as a margin of ≤ 1 mm. Long‐term outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards regression models. Results: Among 303 eligible patients, CRM positivity was observed in 26 (8.6%). The 3‐year recurrence‐free survival (RFS) rate was significantly lower in the CRM‐positive group than in the CRM‐negative group (61.5% vs. 82.3%; log‐rank p = 0.003). CRM positivity was independently associated with worse RFS (hazard ratio, 2.35; 95% confidence interval, 1.17–4.71; p = 0.016). In patients with pT3–T4 tumors, recurrence rates were significantly higher in CRM‐positive cases than in CRM‐negative cases (47.6% vs. 21.2%; p = 0.013). CRM status was not significantly associated with overall survival or cumulative incidence of local recurrence ( p = 0.057 and p = 0.706, respectively). Conclusions: CRM positivity is an adverse prognostic factor in Japanese patients with locally advanced rectal cancer undergoing MIS, underscoring the clinical importance of standardized CRM assessment. Trial Registration: Clinical Trials Registry, Identification Number: UMIN00034365
- 27 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
Open AccessPrognostic Impact of Circumferential Resection Margin in Minimally Invasive Surgery for Locally Advanced Rectal Cancer: A Multicenter Prospective Study
Aim: Circumferential resection margin (CRM) status is a well‐established prognostic factor in rectal cancer surgery; however, its long‐term oncological relevance has not been prospectively validated in Japan, where upfront surgery has long been widely used. This study assessed the prognostic impact of CRM in patients with locally advanced rectal cancer treated with minimally invasive surgery. Methods: The PRODUCT trial was a multicenter, prospective, observational study conducted at 18 institutions in Japan. Patients aged ≥ 20 years with clinical stage II or III rectal adenocarcinoma located within 12 cm from the anal verge and scheduled for laparoscopic or robotic surgery were enrolled. CRM positivity was defined as a margin of ≤ 1 mm. Long‐term outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards regression models. Results: Among 303 eligible patients, CRM positivity was observed in 26 (8.6%). The 3‐year recurrence‐free survival (RFS) rate was significantly lower in the CRM‐positive group than in the CRM‐negative group (61.5% vs. 82.3%; log‐rank p = 0.003). CRM positivity was independently associated with worse RFS (hazard ratio, 2.35; 95% confidence interval, 1.17–4.71; p = 0.016). In patients with pT3–T4 tumors, recurrence rates were significantly higher in CRM‐positive cases than in CRM‐negative cases (47.6% vs. 21.2%; p = 0.013). CRM status was not significantly associated with overall survival or cumulative incidence of local recurrence ( p = 0.057 and p = 0.706, respectively). Conclusions: CRM positivity is an adverse prognostic factor in Japanese patients with locally advanced rectal cancer undergoing MIS, underscoring the clinical importance of standardized CRM assessment. Trial Registration: Clinical Trials Registry, Identification Number: UMIN00034365
- Open Access
- 30 March 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 376
Propensity score matched analysis of short-term outcomes in rectal cancer robotic surgery: Hugo RAS versus da Vinci systems
The Hugo RAS system (Hugo), comprising an open surgical console and independent arm carts was launched into the surgical robotics market following the da Vinci surgical system (da Vinci). This study was designed to disclose the feasibility of rectal surgery using Hugo vs. da Vinci systems by assessing short-term outcomes. Between September 2019 and October 2025, 211 patients underwent robotic surgery for non-metastatic rectal cancer. The outcomes of 81 Hugo-assisted and 130 da Vinci-assisted robotic surgeries were compared. The incidence of postoperative complications classified as Clavien–Dindo (CD) grade III or higher was the primary outcome. Secondary outcomes were blood loss, operative time, console time, positive circumferential resection margin (CRM), postoperative hospital stay, and mortality. Hugo and da Vinci cases were compared using 1:1 propensity score matching, balancing for age, sex, BMI, ASA-PS, tumor location, clinical T and N stage, preoperative therapy, surgeon experience, console experience and sphincter preservation. After matching, each group included 56 patients with comparable pretreatment characteristics. There were no significant differences between the Hugo and da Vinci groups in CD grade ≥ III complications (7.1% vs. 8.9%, p = 1.000), blood loss, operative time, console time, CRM positivity, postoperative hospital stay, or mortality. No open conversions occurred in either group. The Hugo system enables feasible rectal surgery with no significant differences in short-term outcomes compared with those achieved using the da Vinci system.
- 30 March 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 376
Open AccessPropensity score matched analysis of short-term outcomes in rectal cancer robotic surgery: Hugo RAS versus da Vinci systems
The Hugo RAS system (Hugo), comprising an open surgical console and independent arm carts was launched into the surgical robotics market following the da Vinci surgical system (da Vinci). This study was designed to disclose the feasibility of rectal surgery using Hugo vs. da Vinci systems by assessing short-term outcomes. Between September 2019 and October 2025, 211 patients underwent robotic surgery for non-metastatic rectal cancer. The outcomes of 81 Hugo-assisted and 130 da Vinci-assisted robotic surgeries were compared. The incidence of postoperative complications classified as Clavien–Dindo (CD) grade III or higher was the primary outcome. Secondary outcomes were blood loss, operative time, console time, positive circumferential resection margin (CRM), postoperative hospital stay, and mortality. Hugo and da Vinci cases were compared using 1:1 propensity score matching, balancing for age, sex, BMI, ASA-PS, tumor location, clinical T and N stage, preoperative therapy, surgeon experience, console experience and sphincter preservation. After matching, each group included 56 patients with comparable pretreatment characteristics. There were no significant differences between the Hugo and da Vinci groups in CD grade ≥ III complications (7.1% vs. 8.9%, p = 1.000), blood loss, operative time, console time, CRM positivity, postoperative hospital stay, or mortality. No open conversions occurred in either group. The Hugo system enables feasible rectal surgery with no significant differences in short-term outcomes compared with those achieved using the da Vinci system.
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0023
Ileocecal CD5-Positive Diffuse Large B-Cell Lymphoma Presenting with Acute Obstructive Symptoms: A Case Report
INTRODUCTION: Primary gastrointestinal lymphoma is a rare form of extranodal non-Hodgkin lymphoma, accounting for approximately 1%–4% of all gastrointestinal malignancies. Among primary gastrointestinal lymphomas, involvement of the small intestine accounts for approximately 20%–30% of cases. CD5-positive diffuse large B-cell lymphoma (DLBCL) is a rare variant, representing approximately 5%–10% of all DLBCL cases and is associated with advanced age, extranodal involvement, and poorer prognosis. We report a rare case of ileocecal CD5-positive DLBCL presenting with acute obstructive symptoms.CASE PRESENTATION: An 80-year-old man presented with abdominal pain and fever. Contrast-enhanced CT demonstrated circumferential wall thickening in the ileocecal region with enlarged regional lymph nodes, resulting in marked luminal narrowing and raising suspicion for locally advanced right-sided colon cancer presenting with acute obstructive symptoms. Emergency laparoscopic right hemicolectomy was performed. Intraoperatively, the tumor appeared hard and showed dense adhesion to the duodenum, with suspected duodenal involvement. The gross specimen revealed an 8 × 7 × 4-cm ulcerated mass arising from the terminal ileum. Histopathology confirmed CD5-positive DLBCL (non-germinal center B-cell type), and regional lymph nodes were histologically negative (0/11). The postoperative course was uneventful, and the patient was referred to the hematology department. PET-CT was initially recommended but deferred by the patient; later imaging suggested disseminated disease, and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy was initiated, although the long-term outcome could not be confirmed.CONCLUSIONS: Malignant lymphoma should be considered in the differential diagnosis of acute obstructive symptoms, even when imaging findings suggest carcinoma. Prompt surgical intervention can facilitate definitive diagnosis and timely referral for systemic therapy in selected cases.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.26-0023
Open AccessIleocecal CD5-Positive Diffuse Large B-Cell Lymphoma Presenting with Acute Obstructive Symptoms: A Case Report
INTRODUCTION: Primary gastrointestinal lymphoma is a rare form of extranodal non-Hodgkin lymphoma, accounting for approximately 1%–4% of all gastrointestinal malignancies. Among primary gastrointestinal lymphomas, involvement of the small intestine accounts for approximately 20%–30% of cases. CD5-positive diffuse large B-cell lymphoma (DLBCL) is a rare variant, representing approximately 5%–10% of all DLBCL cases and is associated with advanced age, extranodal involvement, and poorer prognosis. We report a rare case of ileocecal CD5-positive DLBCL presenting with acute obstructive symptoms.CASE PRESENTATION: An 80-year-old man presented with abdominal pain and fever. Contrast-enhanced CT demonstrated circumferential wall thickening in the ileocecal region with enlarged regional lymph nodes, resulting in marked luminal narrowing and raising suspicion for locally advanced right-sided colon cancer presenting with acute obstructive symptoms. Emergency laparoscopic right hemicolectomy was performed. Intraoperatively, the tumor appeared hard and showed dense adhesion to the duodenum, with suspected duodenal involvement. The gross specimen revealed an 8 × 7 × 4-cm ulcerated mass arising from the terminal ileum. Histopathology confirmed CD5-positive DLBCL (non-germinal center B-cell type), and regional lymph nodes were histologically negative (0/11). The postoperative course was uneventful, and the patient was referred to the hematology department. PET-CT was initially recommended but deferred by the patient; later imaging suggested disseminated disease, and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy was initiated, although the long-term outcome could not be confirmed.CONCLUSIONS: Malignant lymphoma should be considered in the differential diagnosis of acute obstructive symptoms, even when imaging findings suggest carcinoma. Prompt surgical intervention can facilitate definitive diagnosis and timely referral for systemic therapy in selected cases.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Purpose:The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM.Experimental Design:This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed.Results:Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance.Conclusions:This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements.See related commentary by Bent et al., p. 5117
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Clinical characteristics of patients with local regrowth
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Clinical characteristics of patients with local regrowth
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Yield of plasma cell-free DNA and circulating tumor DNA detection status in the 412 samples included in this study.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Detailed patient characteristics and the clinical course of each patient.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Detailed patient characteristics and the clinical course of each patient.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Association between circulating tumor DNA levels and pathological characteristics in patients with non-complete response at the final re-staging who underwent surgery
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Treatment and pathology outcomes in patients with non-complete response who underwent surgery
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial
Treatment and pathology outcomes in patients with non-complete response who underwent surgery
- Open Access
- 19 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6603
Robotic-Assisted Total Pelvic Exenteration for Rectal Cancer Using the Hugo™ RAS System: First Case Report
Introduction: Total pelvic exenteration (TPE) is a radical procedure for advanced pelvic malignancies involving adjacent organs. The Hugo™ RAS System is a novel robotic platform, but its application in TPE has not previously been reported. We describe the first case of robotic-assisted TPE using Hugo™ RAS in a patient with locally advanced rectal cancer invading the prostate. Methods: A 69-year-old male with mucous and bloody stools was diagnosed with cT4b (prostate, levator ani muscle) N0M0 rectal cancer. After short-course radiotherapy (25 Gy/5 fractions), robotic-assisted TPE was performed. Port placement was planned to coincide with future colostomy and urostomy sites to minimize abdominal wall trauma. En bloc resection was achieved, followed by pelvic reconstruction with a gluteus maximus musculocutaneous flap and fascia lata autograft. Urinary diversion was completed with a robotic intracorporeal Wallace-type ileal conduit. Results: The operation lasted 17 h 56 min, with 175 mL blood loss. Postoperatively, Clavien–Dindo grade IIIa paralytic ileus occurred but was managed conservatively. Pathology revealed pT4b (prostate) N1a M0 disease with negative circumferential margin (11 mm). No recurrence was observed at 9 months. Conclusions: This case highlights the technical feasibility and safety of Hugo™ RAS-assisted TPE. Further clinical experience is needed to confirm reproducibility and oncologic safety.
- 19 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6603
Open AccessRobotic-Assisted Total Pelvic Exenteration for Rectal Cancer Using the Hugo™ RAS System: First Case Report
Introduction: Total pelvic exenteration (TPE) is a radical procedure for advanced pelvic malignancies involving adjacent organs. The Hugo™ RAS System is a novel robotic platform, but its application in TPE has not previously been reported. We describe the first case of robotic-assisted TPE using Hugo™ RAS in a patient with locally advanced rectal cancer invading the prostate. Methods: A 69-year-old male with mucous and bloody stools was diagnosed with cT4b (prostate, levator ani muscle) N0M0 rectal cancer. After short-course radiotherapy (25 Gy/5 fractions), robotic-assisted TPE was performed. Port placement was planned to coincide with future colostomy and urostomy sites to minimize abdominal wall trauma. En bloc resection was achieved, followed by pelvic reconstruction with a gluteus maximus musculocutaneous flap and fascia lata autograft. Urinary diversion was completed with a robotic intracorporeal Wallace-type ileal conduit. Results: The operation lasted 17 h 56 min, with 175 mL blood loss. Postoperatively, Clavien–Dindo grade IIIa paralytic ileus occurred but was managed conservatively. Pathology revealed pT4b (prostate) N1a M0 disease with negative circumferential margin (11 mm). No recurrence was observed at 9 months. Conclusions: This case highlights the technical feasibility and safety of Hugo™ RAS-assisted TPE. Further clinical experience is needed to confirm reproducibility and oncologic safety.